Gemphire Therapeutics Inc. (GEMP) Trading at $10.11 after Increase on Jun, 29

June 29, 2018 - By Michael Lund

Gemphire Therapeutics Inc. (NASDAQ:GEMP) trading at $10.11 after increase. The move was reported on Jun, 29 by Barchart.com. The company has $143.89M market cap. At $10.72 PT, the company’s valuation could be $8.63 million more.

On August, 13 Gemphire Therapeutics Inc. (NASDAQ:GEMP)’s earnings release is awaited by WallStreet, according to RTT. The earnings per share diference is $0.17 or 22.97 % up from last years number. Previous year: $-0.74; Analysts forcast: $-0.57. Analysts at Wall Street see Gemphire Therapeutics Inc.’s -1.72 % EPS growth compared to $-0.58 earnings per share for last quarter.

For more Gemphire Therapeutics Inc. (NASDAQ:GEMP) news posted briefly go to: Benzinga.com, Benzinga.com, Benzinga.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “5 Stocks Moving In Thursday’s After-Hours Session” posted on June 21, 2018, “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” on June 29, 2018, “42 Biggest Movers From Yesterday” with a publish date: June 13, 2018, “Mid-Morning Market Update: Markets Open Higher; Constellation Brands Earnings Miss Estimates” and the last “Jefferies sees more headroom for Gemphire, up 97%” with publication date: June 29, 2018.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis .The company has $143.89 million market cap. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH.Currently it has negative earnings.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: